Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Primary source
techcrunch.com ↗
Overview
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Source
Originally published at techcrunch.com.
Related Articles
From our network: explore the AI assistant platform behind this site.
Visit tunx.ai →
Note: This story is aggregated and summarized from the primary source linked above; the original publisher retains all rights. Details may evolve after publication — always confirm against the source. Nothing here is professional, legal or investment advice.
